Article
Brochure
Executive Resource
Video
Ext. PublicationBiopharma Growth Reflects a Resilient 2024
Never miss a thing.
Sign up to receive our insights newsletter.
As the biopharma industry continues to demonstrate resilience and growth with venture investments and IPO activity surpassing 2023 benchmarks, J.P. Morgan’s recent report offered cautious optimism for the future. Biopharma deal activity remains robust, and key trends reveal shifts in deal economics and the focus of venture funding, signaling an evolving market landscape.
Resurgence in Venture Investments
Through Q3 2024, biopharma therapeutics attracted $20.8 billion in venture investments across 319 funding rounds. While Q3’s $6.6 billion is slightly below Q3 2023’s $6.9 billion, full-year projections point to sustained upward momentum. Notably, high-dollar rounds that focused on advanced companies led this resurgence, reflecting confidence in the sector’s potential.
Shifting Licensing Economics
Licensing deals in biopharma saw a significant shift, with upfront payments comprising only 5% of total announced deal values. Total announced deal value for licensing partnerships reached $115 billion through Q3, underscoring the sector’s strategic focus on milestone-driven deal structures.
M&A Volatility Persists
Mergers and acquisitions remained dynamic, with 21 transactions totaling $8.9 billion announced in Q3. This reflects ongoing volatility in M&A activity, highlighting the strategic considerations companies are making amid market fluctuations.
Biopharma IPOs See Growth
IPO activity in 2024 has already outpaced 2023’s full-year totals. By Q3, 16 biopharma companies raised $3 billion through IPOs on NASDAQ and NYSE, compared to $2.7 billion raised from 13 IPOs in 2023. This resurgence in public offerings signals renewed investor confidence and presents opportunities for capital infusion into earlier-stage ventures.
Looking Ahead
The biopharma sector’s strong performance across venture funding, licensing and IPOs underscores its adaptability in a dynamic market environment. As companies navigate new deal structures and capitalize on innovation opportunities, the outlook for biopharma remains promising. Contact us to learn how we can help you navigate the opportunities ahead.
©2025